NYSE · RCUS
Arcus Biosciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RCUS: Nov 04, 2026
Arcus Biosciences, Inc. Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.92. The reported EPS for the same quarter last year was $-1.27.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.92 | $-0.89 | $-1.00 | 7 |
| Dec 2026 | $-0.88 | $-0.82 | $-0.96 | 6 |
| Mar 2027 | $-0.84 | $-0.78 | $-0.88 | 3 |
| Jun 2027 | $-0.80 | $-0.73 | $-0.87 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks · MarketBeat- Fintel · Oct 23, 6:02 PM EDTArcus Biosciences, Inc. Closes Public Offering of 16,428,572 Shares of Common Stock for Net Proceeds of Approximately $269.7 millionOn October 21, 2026, Arcus Biosciences, Inc. entered into an underwriting agreement with Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein, relating to the public offering, issuance and sale of 14,285,715
- RTTNews · Oct 22, 11:11 AM EDTArcus Biosciences Prices $250 Mln Public Offering At $17.50/Share(RTTNews) – Arcus Biosciences, Inc. (RCUS), a late-stage biopharmaceutical company developing treatments for cancer and immune diseases, on Wednesday priced a public offering of 14.28 million common shares at $17.50 each.
- Fintel · Oct 22, 1:08 AM EDTArcus Biosciences, Inc. Estimates $694.0 million in Cash, Cash Equivalents and Marketable Securities as of September 30, 2026Arcus Biosciences, Inc. announced preliminary estimates indicating that the company had approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026. This estimate is based upon information available to the company as of October 21, 20
- Zacks · Oct 21, 10:00 AM EDTCan Expanding Ivonescimab Development Unlock SMMT's Growth Potential?Summit is expanding ivonescimab beyond lung cancer into colorectal, bladder, kidney and other cancers, backed by promising early data and collaboration deals.
- Zacks · Oct 21, 9:00 AM EDTBiogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseBiogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- MarketBeat · Oct 21, 5:02 AM EDTArcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor DayFrom laggards to leaders: Small caps on the riseArcus Biosciences (NYSE:RCUS) presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line and later-line clear cell renal ce
- Zacks · Oct 20, 9:00 AM EDTArcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseArcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Fintel · Oct 14, 5:17 PM EDTJP Morgan Initiates Coverage of Arcus Biosciences at OverweightFintel reports that on October 14, 2026, JP Morgan initiated coverage of Arcus Biosciences (NYSE:RCUS) with a Overweight recommendation.Prior to this rating action, the stock closed at $22.51 on October 13, 2026. This latest close of $22.51 represents a price change of -7.29% ove
- BNK Invest · Sep 11, 4:36 PM EDTOversold Conditions For Arcus Biosciences (RCUS)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- BNK Invest · Sep 11, 4:19 PM EDTArcus Biosciences (RCUS) Shares Cross Below 200 DMAIn trading on Friday, shares of Arcus Biosciences Inc (Symbol: RCUS) crossed below their 200 day moving average of $24.72, changing hands as low as $24.32 per share. Arcus Biosciences Inc shares are currently trading down about 6% on the day. The chart below shows the one year
- BNK Invest · Sep 11, 12:43 PM EDTFriday's ETF with Unusual Volume: IJSThe iShares S&P Small-Cap 600 Value ETF is seeing unusually high volume in afternoon trading Friday, with over 1.1 million shares traded versus three month average volume of about 243,000. Shares of IJS were up about 0.7% on the day. Components of that ETF with the highest
- The Motley Fool · Aug 12, 9:14 PM EDTArcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Arcus Biosciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.